Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

SpringWorks Therapeutics

Explore full profile

Clinical-stage biopharmaceutical company that identifies and advances promising science and pioneers efficient pathways

New York City, United StatesFounded 2017Biotech & Life Sciences
Valuation $3.26B Market cap · 2025
Revenue $192M Latest reported FY
Total funding $100–500M Disclosed equity funding

About SpringWorks Therapeutics

SpringWorks Therapeutics is a clinical stage biopharmaceutical company focused on developing and commercializing precision medicines for patients with rare diseases and cancer. The company employs a precision medicine approach, which means they tailor treatments based on the genetic and molecular profile of the disease. This approach aims to improve the efficacy and safety of treatments for underserved patient populations suffering from devastating conditions. SpringWorks operates in the biopharmaceutical market, targeting both rare diseases and oncology. Their business model involves acquiring, developing, and commercializing innovative therapies. Revenue is generated through the successful development and commercialization of these therapies, often in collaboration with other pharmaceutical companies. The company serves a niche market of patients with specific genetic profiles, offering them potentially life-changing treatments that are not widely available. SpringWorks is actively involved in clinical trials, including Phase 1b and 2 studies, to evaluate the efficacy and safety of their drug candidates. Keywords: precision medicine, biopharmaceutical, rare diseases, cancer, clinical trials, genetic profiling, oncology, drug development, underserved patients, innovative therapies.

Source: Dealroom company data

At a glance

Founded
2017
Headquarters
New York City, United States
Listing
IPO 2019
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

Series B and later8 investors entered at this stage

  • GSK
  • Perceptive Advisors
  • EcoR1 Capital
  • ArrowMark Partners
  • Deerfield
  • Samsara BioCapital
  • Boxer Capital
  • Invus
Employees mapped 352 incl. 1 AI specialist
Founders Hidden — book a demo/100 quality score
Key operators 32 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇺🇸 United States92.8%
🇩🇪 Germany4.6%
🇨🇭 Switzerland1%
🇮🇹 Italy0.7%
🇬🇧 United Kingdom0.7%
5 countries shown
Web traffic by country
14K monthly visits
across markets
🇺🇸 United States92.1%
🇮🇳 India9.3%
Top 2 markets shown

Patents

Estimated portfolio value
$26M

58 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about SpringWorks Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See SpringWorks Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.